Novartis Pays Spark $105M Up Front for Gene Therapy Rights Outside US – Xconomy
Xconomy |
Novartis Pays Spark $105M Up Front for Gene Therapy Rights Outside US
Xconomy Spark Therapeutics is licensing to Novartis the rights to its gene therapy outside of the U.S., a deal that puts the treatment for a rare, inherited form of blindness in the hands of a large pharmaceutical company with the resources to commercialize … Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal Novartis strikes $170m deal for ex-US rights to gene therapy for blindness Spark Therapeutics signs $170M+ deal with Novartis for blindness gene therapy |
